Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 259
- Registration Number
- NCT00725491
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- Conditions
- NeonatesPregnancy
- Interventions
- Drug: Corifollitropin alpha (MK-8962, Org 36286) 150 ugDrug: Corifollitropin alpha (MK-8962, Org 36286) 100 ugBiological: Recombinant follicle stimulating hormone (recFSH)Biological: Human chorionic gonadotprophin (hCG).
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 15
- Registration Number
- NCT00702520
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 424
- Registration Number
- NCT00667069
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Henri Mondor, Creteil, France
🇫🇷Clinique du Pont de Chaume, Montauban, France
🇫🇷Centre Henri Becquerel, Rouen, France
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
- Conditions
- FatigueBreast CancerSleep Disorders
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 86
- Registration Number
- NCT00659373
- Locations
- 🇺🇸
Front Range Cancer Specialists, Fort Collins, Colorado, United States
🇺🇸New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States
🇺🇸Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States
Administration of GnRH Antagonist to Oocyte Donation Recipients
- Conditions
- PregnancyEmbryo Implantation
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Centro Ginecologia y Obstetricia.
- Target Recruit Count
- 100
- Registration Number
- NCT00635258
- Locations
- 🇪🇸
CEGIOB, Valencia, Spain
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
- Conditions
- Precocious Puberty
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 37
- Registration Number
- NCT00564850
- Locations
- 🇫🇷
Hôpital Hotel-Dieu (CHU), Angers, France
🇫🇷Hôpital Saint-Jacques, Besancon, France
🇫🇷Medical Centre, Bordeaux, France
Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Shaare Zedek Medical Center
- Registration Number
- NCT00542126
- Locations
- 🇮🇱
IVF unit, Shaare-Zedek Medical Center, Jerusalem, Israel
GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2007-08-15
- Lead Sponsor
- V.K.V. American Hospital, Istanbul
- Target Recruit Count
- 570
- Registration Number
- NCT00516490
- Locations
- 🇹🇷
Amerikan Hastanesi Tüp Bebek Merkezi, Istanbul, Turkey
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin
- Conditions
- Infertility
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2007-04-18
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 182
- Registration Number
- NCT00461916
- Locations
- 🇮🇷
Dr. Shariati Hospital, Tehran, Iran, Islamic Republic of
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 25
- Registration Number
- NCT00444639
- Locations
- 🇳🇱
AMC Amsterdam, Amsterdam, Netherlands
🇳🇱Diaconessenhuis Leiden, Leiden, Netherlands
🇳🇱Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.